WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTC:ACTC) commented today on its technology platform. The Company noted that it believes it has the only technology that can produce stem cell lines of all types without the destruction of the embryo, which should increase the likelihood of receiving federal funding for clinical development. In addition, one of the Company’s licensees, International Stem Cell Corporation (ISCO.ob), is using Advanced Cell’s parthenogenesis technology, which has the capability of developing some types of stem cells using genetic engineering.
